#Latest news with #immunologicalDiseasesBloomberg4 days agoBusinessBloombergSanofi to Buy Blueprint for $9.1 Billion Equity ValueSanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio. Sanofi will pay $129 per share in cash, the companies said in a statement Monday. That represents a 27% premium to Blueprint's closing price on Friday.
Bloomberg4 days agoBusinessBloombergSanofi to Buy Blueprint for $9.1 Billion Equity ValueSanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio. Sanofi will pay $129 per share in cash, the companies said in a statement Monday. That represents a 27% premium to Blueprint's closing price on Friday.
4 days ago
